Company Overview - He Mei Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with Guotou Securities International as the sole sponsor [1] - The company focuses on the discovery and development of proprietary small molecule drugs targeting autoimmune diseases and tumors, with a pipeline of seven small molecule candidates [1] Core Products - The core product Mufemilast is a self-developed PDE4B expression blocker and PDE4 inhibitor, approved for new drug application (NDA) in September 2025 for the treatment of moderate to severe plaque psoriasis [1] - The second core product Hemay022 is a globally owned Class 1 small molecule inhibitor targeting both EGFR and HER2, with a Phase III clinical trial for advanced ER+/HER2+ breast cancer planned for NDA submission in 2027 [1] Technology and Market Potential - The company has established a comprehensive technical system covering the entire process of small molecule drug development, including modular compound library construction, biomarker animal model screening, tumor microenvironment activation combination chemotherapy design, and differentiated clinical design [2] - The global and Chinese autoimmune disease drug markets are showing significant growth trends, with the Chinese autoimmune disease drug market expected to reach USD 26.3 billion by 2032, and the psoriasis drug market projected to reach RMB 87.1 billion by 2032 [2]
和美药业递表港交所 国投证券国际为独家保荐人
Zheng Quan Shi Bao Wang·2025-12-02 00:41